Encephalitis after Yellow Fever Vaccination

Cannon, D. A.

doi:10.1136/bmj.1.4921.1090-b

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No serious or minor AEs were identified, which does not seem credible. No conclusions can be drawn from the brief note by Cannon,23 who stated that 35,000 vaccinations ("mostly infants") had been given with Rockefeller or Burroughs Wellcome (London, currently owned by GlaxoSmithKline) 17D vaccine in Lagos with no serious adverse reactions reported. There was no statement about surveillance methods.…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review

Thomas¹,

Lorenzetti²,

Spragins³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Yellow fever vaccine provides long-lasting immunity. Rare serious adverse events after vaccination include neurologic or viscerotropic syndromes or anaphylaxis. We conducted a systematic review of adverse events associated with yellow fever vaccination in vulnerable populations. Nine electronic bibliographic databases and reference lists of included articles were searched. Electronic databases identified 2,415 abstracts for review, and 32 abstracts were included in this review. We identified nine studies of adverse events in infants and children, eight studies of adverse events in pregnant women, nine studies of adverse events in human immunodeficiency virus-positive patients, five studies of adverse events in persons 60 years and older, and one study of adverse events in individuals taking immunosuppressive medications. Two case studies of maternal-neonate transmission resulted in serious adverse events, and the five passive surveillance databases identified very small numbers of cases of yellow fever vaccine-associated viscerotropic disease, yellow fever vaccine-associated neurotropic disease, and anaphylaxis in persons ! 60 years. No other serious adverse events were identified in the other studies of vulnerable groups. BACKGROUND

show abstract

Section: Resultsmentioning

confidence: 98%

“…Nine studies investigated YFV AEs in infants and children. [18][19][20][21][22][23][24][25][26] We identified four RCTs that used active surveillance for AEs. [18][19][20][21] Two of the RCTs 18,20 involving children are at low risk of bias, and two RCTs 19,21 are at moderate risk of bias.…”

Section: Resultsmentioning

confidence: 99%